Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

EU in talks to secure Sanofi deal for coronavirus vaccine

share with twitter share with LinkedIn share with facebook
07/31/2020 | 11:56pm EDT
FILE PHOTO: Sanofi logo is seen in Paris

Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine for the 27-country European Union.

Armed with an emergency fund of more than 2 billion euros (£1.80 billion), the European Commission wants to strike deals with up to six drugmakers for their vaccines for their 450 million citizens against the coronavirus that has killed 674,000 people worldwide.

The Commission said the aim of the talks with Sanofi was to clinch an advance purchase deal.

"The envisaged contract with Sanofi would provide for an option for all EU Member States to purchase the vaccine," the Commission said in a statement.

"It is envisaged that, once a vaccine has proven to be safe and effective against COVID-19, the Commission would have a contractual framework in place for the purchase of 300 million doses, on behalf of all EU member states."

A Commission spokesman said he could not comment on when a deal would be announced and the possible price for the vaccine, calling it a quite promising step towards an eventual agreement.

Sanofi is working on two vaccine projects including one in partnership with GlaxoSmithKline.

The companies said the doses would be manufactured in European countries including France, Belgium, Germany and Italy.

Sanofi is leading the clinical development of the vaccine and expects to start a trial by the end of this year.

Earlier this week, EU talks with Sanofi, Pfizer and Johnson & Johnson hit an impasse over price, payment method and potential liability costs, EU officials told Reuters.

Other pharmaceutical companies talking to the EU include France's Valneva, Moderna and biotech firms BioNTech and Germany's CureVac.

By Foo Yun Chee

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 2.73% 71 Delayed Quote.109.56%
GLAXOSMITHKLINE PLC -1.43% 1569.8 Delayed Quote.-11.76%
MODERNA, INC. -2.43% 67.83 Delayed Quote.246.78%
PFIZER LIMITED -0.28% 4534.3 End-of-day quote.7.34%
PFIZER, INC. -0.42% 38.17 Delayed Quote.-2.58%
SANOFI -1.37% 86.99 Real-time Quote.-2.93%
VALNEVA SE -2.34% 5.42 Real-time Quote.110.89%
share with twitter share with LinkedIn share with facebook
02:04pEU to enter contract talks with J&J over 200 million doses of potential COVID..
10:11aEUROPE : European stocks end four-day winning run as UK's FTSE drags
08/13GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
08/12GLAXOSMITHKLINE : UBS maintains a Buy rating
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
08/11Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in Au..
08/10GLAXOSMITHKLINE : CureVac Sets IPO at 13.3 Million Shares; Sees Pricing at $14-$..
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
08/10Biotech company CureVac aims to raise up to $245 mln in U.S. IPO
More news
Sales 2020 35 040 M 45 800 M 45 800 M
Net income 2020 4 781 M 6 249 M 6 249 M
Net Debt 2020 22 747 M 29 732 M 29 732 M
P/E ratio 2020 15,2x
Yield 2020 5,10%
Capitalization 78 127 M 102 B 102 B
EV / Sales 2020 2,88x
EV / Sales 2021 2,75x
Nbr of Employees 99 437
Free-Float 91,3%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 1 867,21 GBX
Last Close Price 1 569,80 GBX
Spread / Highest target 42,7%
Spread / Average Target 18,9%
Spread / Lowest Target -2,09%
EPS Revisions
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.75%394 028
ROCHE HOLDING AG1.08%297 694
PFIZER, INC.-2.17%212 995
MERCK & CO., INC.-9.09%209 118
NOVARTIS AG-15.76%187 147